Retatrutide

Retatrutide is a synthetic, experimental peptide that has been developed as a multi-pathway agonist. It is currently being studied for its potential effects on receptor-mediated signaling, molecular dynamics, and endocrine functions in preclinical research models. By activating multiple target receptor subtypes, Retatrutide exhibits broad systemic effects that are being investigated for their relevance within endocrine and pathway-directed research.
Jastreboff A.M. et al., 2023

History

The development of Retatrutide builds on decades of research within peptide signaling science. Early studies with single-pathway agonists demonstrated their role in downstream signaling and receptor activity. Later studies extended this to dual-agonist models, eventually paving the way for Retatrutide, which uniquely combines three pathway targets.

This multi-agonist design represents a new direction within peptide research, aimed at studying broader receptor-mediated modulation in preclinical laboratory settings.
Coskun T. et al., 2022

Retatrutide Structure

CAS #: 2381089-83-2
Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: 4845.44 g/mol
PubChem ID: 474492335

Research findings

Retatrutide has been investigated in endocrine and systemic models, with studies describing its influence on receptor binding kinetics, downstream signaling cascades, lipid pathway dynamics, and integrated endocrine pathways. Research also points to involvement in multisystem signaling and pathway characterization within preclinical and laboratory settings.

Key Research Areas

Endocrine
• Receptor binding
• Signaling processes
• Signaling cascades

Pathways
• Target receptor subtypes
• Modulation
• Dynamics

Vascular
• Lipid pathways
• Hepatic signaling
• Biomarkers

Systemic
• Multi-pathway signaling
• Biological resilience
• Characterization

Together, these findings suggest a broad experimental potential for DP3-R within endocrine, vascular and systemic models. By activating multiple pathway targets, it provides a versatile research platform for studying downstream signaling cascades and integrated molecular responses within diverse biological systems.

Jastreboff A.M. et al., New England Journal of Medicine, 2023

References

Jastreboff A.M. et al. (2023). Triple-hormone receptor agonist retatrutide in obesity — a randomized, controlled trial. New England Journal of Medicine, 389(1), 11–24.

Coskun T. et al. (2022). Retatrutide: A triple-hormone receptor agonist for obesity and diabetes. Diabetes, 71(7), 1435–1449.